Investor Relations

NEO:CYBN

view stock
Cybin is a leading biotech company in the psychedelic therapeutic sector. Our team is focused on the development of mental healthcare treatment with a single-minded goal to dramatically improve patient outcomes versus currently available pharmacotherapies. Our work includes the development of new drug molecules, with a focus on optimizing treatment outcomes through: innovative drug delivery systems, concurrent therapy regimens, and technology-drive patient analytics. Learn more about how we are working to revolutionize mental healthcare in our three pillar strategy.
NEO:CYBN

view stock

Invest in Cybin

2

phase 1 trials in 2021

C$

88

M

raised to date to progress m&a strategy and clinical trials

10

patent filings

10

Patent filings

2

phase 1 trials in 2021

C$

88

M

raised to date to progress
m&a strategy

Investor Presentation

Last updated: 04.15.2021
Cybin Inc. Corporate Presentation
Download presentation

2021 Financial Highlights and Business Update

Download

SEDAR Profile

Visit
press releases
4.13.2021

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Read more >
3.30.2021

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Read more >
3.22.2021

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Read more >
read more

Corporate Governance

close

Our site uses cookies. Learn more about our privacy policy.

I accept the use of cookies